GSA Capital Partners LLP Boosts Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL)

GSA Capital Partners LLP boosted its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 991.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 241,866 shares of the company's stock after acquiring an additional 219,703 shares during the period. GSA Capital Partners LLP owned 0.08% of AbCellera Biologics worth $629,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ABCL. Arcadia Investment Management Corp MI bought a new stake in AbCellera Biologics during the third quarter valued at about $26,000. Evergreen Capital Management LLC bought a new stake in shares of AbCellera Biologics in the 2nd quarter valued at about $32,000. NBC Securities Inc. grew its position in shares of AbCellera Biologics by 56.0% in the 3rd quarter. NBC Securities Inc. now owns 11,420 shares of the company's stock worth $29,000 after buying an additional 4,100 shares during the last quarter. Ballentine Partners LLC bought a new position in shares of AbCellera Biologics during the 3rd quarter worth approximately $54,000. Finally, B. Riley Wealth Advisors Inc. lifted its position in AbCellera Biologics by 104.8% during the second quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company's stock valued at $64,000 after acquiring an additional 11,000 shares during the last quarter. Institutional investors own 61.42% of the company's stock.

AbCellera Biologics Trading Up 2.3 %

ABCL stock traded up $0.06 during midday trading on Tuesday, reaching $2.71. The stock had a trading volume of 1,818,149 shares, compared to its average volume of 1,696,711. AbCellera Biologics Inc. has a 52-week low of $2.34 and a 52-week high of $6.05. The company's fifty day simple moving average is $2.68 and its 200 day simple moving average is $2.98.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The business had revenue of $6.51 million during the quarter, compared to analyst estimates of $8.95 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. Research analysts expect that AbCellera Biologics Inc. will post -0.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ABCL. Stifel Nicolaus restated a "buy" rating and issued a $12.00 target price (down previously from $14.00) on shares of AbCellera Biologics in a research note on Tuesday, November 5th. Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a report on Tuesday, November 5th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.